The Hong Kong University of Science and Technology (HKUST) announced today that  its School of Engineering researchers have developed Mixture of Modality Experts (MOME), a groundbreaking large artificial intelligence (AI) model for non-invasive breast cancer diagnosis. Trained on the China’s largest multiparametric MRI (mpMRI) breast cancer dataset, MOME achieves expert-level accuracy in classifying tumor malignancy, comparable to that of radiologists with five+years of experience. This innovative solution is now undergoing extensive clinical validation across more than ten hospitals and partner institutions, including Shenzhen People’s Hospital, the Guangzhou First Municipal People's Hospital, and Yunnan Cancer Center, to validate its effectiveness and ensure real-world applicability.

Researchers at Tel Aviv University’s Gray Faculty of Medical & Health Sciences conducted a series of experiments using advanced technologies, focusing on the tumor microenvironment in advanced stages of breast cancer. They found that immune system cells called neutrophils are recruited by the tumor environment and support tumor progression in the later stages of the disease. The researchers stated: "In light of our findings, we believe that neutrophils, which are unique to the tumor environment, may serve as targets for the development of new drugs and as biomarkers for advanced-stage breast cancer."

Dr. Nikolaos Koundouros, a postdoctoral associate in the Department of Pharmacology at Weill Cornell Medicine, has been awarded a 2025 Tri-Institutional Breakout Award for Junior Investigators.

To explore how genetic testing guides precision medicine for both gynecologic cancer patients and clinicians, we spoke with two leading experts: Professor Wu Xiaohua, Professor of Medical Oncology at Fudan University's Obstetrics and Gynecology Hospital, and Professor Du Bin, Chief of Pathology at Shanghai First Maternity and Infant Hospital.

Patients with early-stage HER2+ breast cancer typically receive pre-operative multi-agent chemotherapy and anti-HER2 antibodies, followed by surgery and possibly more chemotherapy. The CompassHER2 pCR trial is evaluating a less intensive, reduced chemotherapy approach, the first large-scale study of its kind, but more follow-up is needed to assess its impact on survival. Meanwhile, researchers are reporting rates of pathologic complete response (pCR) at time of surgery, detailing which patients are most likely to benefit from the new approach.